Roots Analysis has done a detailed
study on Manufacturing
Market Continuous (Small Molecules and
Biologics), 2020 – 2030.”, covering key aspects of the industry and identifying future
growth opportunities.
To order this 310+
page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Key Market Insights
§
§
§
§
§
§
§
§
§
§
For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Table of Contents
TABLE OF CONTENTS
1. PREFACE
1.1. Scope of
the Report
1.2. Research
Methodology
1.3. Chapter
Outlines
2. EXECUTIVE
SUMMARY
3. INTRODUCTION
3.1. Chapter
Overview
3.2. Historical
Evolution of Continuous Manufacturing
3.3. Continuous
Manufacturing in the Pharmaceutical Industry
3.3.1. Regulatory
Landscape
3.3.2. Early
Adopters of Continuous Manufacturing
3.3.3. Anticipated
Shift to Continuous Manufacturing
3.3.4. Advantages
of Continuous Manufacturing
3.3.5. Key
Challenges Associated with Continuous Manufacturing
3.3.6. Future
Perspectives
4. MARKET
LANDSCAPE
4.1. Chapter
Overview
4.2. Companies
with Expertise in Continuous Manufacturing: Overall Market Landscape
4.2.1. Analysis by
Year of Establishment
4.2.2. Analysis by
Company Size
4.2.3. Analysis by
Purpose of Manufacturing
4.2.4. Analysis by
Scale of Operation
4.2.5. Analysis by
Location of Headquarters
4.2.6. Analysis by
Location of Continuous Manufacturing Facilities
4.2.7. Analysis by
Type of Drug Molecule
4.2.8. Analysis by
Type of Continuous Manufacturing Related Service
4.2.9. Analysis by
Type of Dosage Form
4.2.10. Heat Map:
Analysis by Company Size and Location of Headquarters
4.2.11. Information
on Production Capacity
4.2.12. Logo
Landscape: Analysis by Year of Establishment and Company Size
4.2.13. Grid Representation: Analysis by Scale of
Operation, Type of Continuous Manufacturing Related Service and Type of Dosage
Form
4.2.14. Geographical Map: Analysis by Location of
Continuous Manufacturing Facilities and Type of Drug Molecule
5. COMPANIES WITH EXPERTISE IN CONTINUOUS
MANUFACTURING IN NORTH AMERICA: PROFILES
5.1. Chapter
Overview
5.2. AbbVie
Contract Manufacturing
5.2.1. Company
Overview
5.2.2. Service
Portfolio
5.2.3. Continuous
Manufacturing Capabilities and Facilities
5.2.4. Recent
Developments and Future Outlook
5.3. Cambrex
5.3.1. Company
Overview
5.3.2. Service
Portfolio
5.3.3. Continuous
Manufacturing Capabilities and Facilities
5.3.4. Recent
Developments and Future Outlook
5.4. Patheon
5.4.1. Company
Overview
5.4.2. Service
Portfolio
5.4.3. Continuous
Manufacturing Capabilities and Facilities
5.4.4. Recent
Developments and Future Outlook
5.5. SK biotek
5.5.1. Company
Overview
5.5.2. Service
Portfolio
5.5.3. Continuous
Manufacturing Capabilities and Facilities
5.5.4. Recent
Developments and Future Outlook
6. COMPANIES WITH EXPERTISE IN CONTINUOUS
MANUFACTURING IN EUROPE: PROFILES
6.1. Chapter
Overview
6.2. Ajinomoto
Bio-Pharma Services
6.2.1. Company
Overview
6.2.2. Service
Portfolio
6.2.3. Continuous
Manufacturing Capabilities and Facilities
6.2.4. Recent
Developments and Future Outlook
6.3. Almac
6.3.1. Company
Overview
6.3.2. Service
Portfolio
6.3.3. Continuous
Manufacturing Capabilities and Facilities
6.3.4. Recent
Developments and Future Outlook
6.4. Boehringer
Ingelheim BioXcellence™
6.4.1. Company
Overview
6.4.2. Service
Portfolio
6.4.3. Continuous
Manufacturing Capabilities and Facilities
6.4.4. Recent
Developments and Future Outlook
6.5. CordonPharma
6.5.1. Company
Overview
6.5.2. Service
Portfolio
6.5.3. Continuous Manufacturing
Capabilities and Facilities
6.5.4. Recent
Developments and Future Outlook
6.6. Hovione
6.6.1. Company
Overview
6.6.2. Service
Portfolio
6.6.3. Continuous
Manufacturing Capabilities and Facilities
6.6.4. Recent
Developments and Future Outlook
6.7. Lonza
6.7.1. Company
Overview
6.7.2. Service
Portfolio
6.7.3. Continuous
Manufacturing Capabilities and Facilities
6.7.4. Recent
Developments and Future Outlook
7. COMPANIES WITH EXPERTISE IN CONTINUOUS
MANUFACTURING IN ASIA-PACIFIC: PROFILES
7.1. Chapter
Overview
7.2. Kaneka
7.2.1. Company
Overview
7.2.2. Service
Portfolio
7.2.3. Continuous
Manufacturing Capabilities and Facilities
7.2.4. Recent
Developments and Future Outlook
7.3. WuXi AppTec
7.3.1. Company
Overview
7.3.2. Service
Portfolio
7.3.3. Continuous
Manufacturing Capabilities and Facilities
7.3.4. Recent
Developments and Future Outlook
8. RECENT
PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter
Overview
8.2. Partnership
Models
8.3. List of
Partnerships and Collaborations
8.3.1. Analysis by
Year of Partnership
8.3.2. Analysis by
Type of Partnership
8.3.3. Analysis by
Scale of Operation
8.3.4. Analysis by
Type of Drug Molecule
8.3.5. Analysis by
Type of Continuous Manufacturing Related Service
8.3.6. Analysis by
Type of Dosage Form
8.3.7. Most Active
Players: Analysis by Number of Partnerships
8.3.8. Regional
Analysis
8.3.8.1. Intercontinental
and Intracontinental Agreements
9. RECENT
EXPANSIONS
9.1. Chapter
Overview
9.2. Recent
Expansions
9.2.1. Analysis by
Year of Expansion
9.2.2. Analysis by
Type of Expansion
9.2.3. Analysis by
Expanded Scale of Expansion
9.2.4. Analysis by
Type of Drug Molecule
9.2.5. Analysis by
Type of Continuous Manufacturing Related Service
9.2.6. Analysis by
Type of Dosage Form
9.2.7. Most Active
Players: Analysis by Number of Expansions
9.2.8. Regional
Analysis
9.2.8.1. Analysis by
Location of Expansion Project
10. CAPACITY
ANALYSIS
10.1. Chapter
Overview
10.2. Assumptions
and Methodology
10.3. Global,
Continuous Manufacturing Capacity for Small Molecule APIs
10.3.1. Analysis by
Company Size
10.3.2. Analysis by
Purpose of Manufacturing
10.3.3. Analysis by
Scale of Operation
10.3.4. Analysis by
Location of Headquarters
10.3.4. Analysis by
Location of Continuous Manufacturing Facilities
10.4. Global,
Continuous Manufacturing Capacity for Small Molecule End Products
10.4.1. Analysis by
Company Size
10.4.2. Analysis by
Purpose of Manufacturing
10.4.3. Analysis by
Scale of Operation
10.4.4. Analysis by
Location of Headquarters
10.4.5. Analysis by
Location of Continuous Manufacturing Facilities
10.5. Global,
Continuous Manufacturing Capacity for Biologic
10.5.1. Analysis by
Company Size
10.5.2. Analysis by
Purpose of Manufacturing
10.5.3. Analysis by
Scale of Operation
10.5.4. Analysis by
Location of Headquarters
10.5.5. Analysis by
Location of Continuous Manufacturing Facilities
11. ACADEMIC
GRANT ANALYSIS
11.1. Chapter
Overview
11.2. Scope and
Methodology
11.3. Continuous
Manufacturing: List of Academic Grants
11.3.1. Analysis by
Number of Grants
11.3.2. Analysis by
Activity Code
11.3.3. Analysis by
Grant Amount
11.3.4. Analysis by
Focus Area
11.3.5. Analysis by
Support Period
11.3.6 Popular
Recipient Organizations: Analysis by Number of Grants
11.3.7 Analysis by
Type of Recipient Organization
11.3.8. Analysis by
Funding Institute Centre
11.3.9. Analysis by
Funding Mechanism
11.3.10. Prominent Program Officers: Analysis by Number of
Grants
12. PATENT
ANALYSIS
12.1. Chapter
Overview
12.2. Scope and
Methodology
12.3. Continuous
Manufacturing: Patent Analysis
12.3.1. Analysis by
Publication Year
12.3.2. Analysis by
Geography
12.3.3. Analysis by
CPC Symbols
12.3.4. Emerging
Focus Areas
12.3.5. Analysis by
Type of Applicant
12.3.6. Leading
Players: Analysis by Number of Patents
12.3.7. Continuous
Manufacturing: Three-Dimensional Bubble Analysis
12.3.8. Continuous
Manufacturing: Patent Valuation Analysis
12.3.8.1. Leading Patents: Information by Number of
Citations
13. INITIATIVES OF COMPANIES WITH IN-HOUSE
CONTINUOUS MANUFACTURING CAPABILITIES
13.1. Chapter
Overview
13.2. Continuous
Manufacturing Initiatives of Leading Companies
13.2.1. AbbVie
13.2.1.1. Partnered Initiatives
13.2.1.2 In-House Initiatives
13.2.2. Amgen
13.2.2.1. Partnered Initiatives
13.2.2.2. In-House Initiatives
13.2.3. Bristol-Myers
Squibb
13.2.3.1. Partnered Initiatives
13.2.3.2. In-House Initiatives
13.2.4. GlaxoSmithKline
13.2.4.1. Partnered Initiatives
13.2.4.2. In-House Initiatives
13.2.5. Merck
13.2.5.1. Partnered Initiatives
13.2.5.2. In-House Initiatives
13.2.6. Novartis
13.2.6.1. Partnered Initiatives
13.2.6.2. In-House Initiatives
13.2.7. Pfizer
13.2.7.1. Partnered Initiatives
13.2.7.2. In-House Initiatives
13.2.8. Roche
13.2.8.1. Partnered Initiatives
13.2.8.2. In-House Initiatives
13.2.9. Sanofi
13.2.9.1. Partnered Initiatives
13.2.9.2. In-House Initiatives
14. CASE STUDY:
MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY
14.1. Chapter
Overview
14.2. Historical
Background
14.3. Concept of
Modularization
14.3.1. Types of
Modules
14.3.2. Modular
Construction Process
14.4. Modular
Construction in the Pharmaceutical Industry
14.4.1. Advantages of
Modular Construction in the Pharmaceutical Industry
14.5. Modular
Facility Manufacturers
14.5.1. Distribution
by Industry Served
14.5.2. Distribution
by Geography
14.5.3. Modular
Projects Executed / Undertaken
14.6. Modular
Pharmaceutical Cleanrooms
14.6.1. Cleanroom
Classification and Current Standards
14.6.2. Advantages of
Modular Cleanrooms
14.6.3. Regulations
and Standards Concerning Modular Cleanroom Construction
14.7. Modular
Cleanroom Providers
14.7.1. Distribution
by Industry Served
14.7.2. Distribution
by Geography
14.7.3. Type of
Modular Cleanrooms Offered
15. CASE STUDY:
TECHNOLOGY AND EQUIPMENT PROVIDERS
15.1. Chapter
Overview
15.2. Types of
Continuous Manufacturing Technologies
15.3. Equipment
and Technologies for Continuous Manufacturing Small Molecules and Biologics
15.3.1. Continuous
Blending and Mixing Equipment
15.3.2. Continuous
Granulating Equipment
15.3.3. Continuous
Drying Equipment
15.3.4. Continuous
Compression Equipment
15.3.5. Continuous
Coating Equipment
15.3.6. Continuous
Filtration, Continuous Distillation and Continuous Centrifugation Equipment
15.3.7. Continuous
Chromatography Equipment
15.3.8. Continuous
Reactors / Bioreactors
15.3.9. Full Line
Continuous Platforms
15.3.10. Process Analytical Technologies
15.3.11. Other Technologies
15.4. Logo
Landscape: Analysis of Technology Providers by Number and Type of Equipment
16. CASE STUDY: ROADMAP FOR THE ADOPTION OF
CONTINUOUS MANUFACTURING PROCESSES
16.1. Chapter
Overview
16.2. Key
Strategies for the Adoption of Continuous Manufacturing Processes
16.2. 1. Phase I:
Process Development and Implementation
16.2. 2. Phase II:
Equipment / Technology Development and Installation
16.2. 3. Phase III:
Facility / Plant Development and Establishment
16.2. 4. Phase IV:
Product Development and Manufacturing
17. MARKET
FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter
Overview
17.2. Forecast
Methodology and Key Assumptions
17.3. Overall,
Continuous Manufacturing Market, 2020-2030
17.3.1. Continuous
Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030
17.3.2. Continuous
Manufacturing Market: Distribution by Scale of Operation, 2020-2030
17.3.3. Continuous
Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030
17.3.4. Continuous Manufacturing Market: Distribution
by Type of Continuous Manufacturing Related Service, 2020-2030
17.3.5. Continuous
Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030
17.3.6. Continuous
Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030
17.4. Continuous
Manufacturing Market for Small Molecule, 2020-2030
17.4.1. Distribution
by Purpose of Manufacturing, 2020-2030
17.4.2. Distribution
by Scale of Operation, 2020-2030
17.4.3. Distribution
by Type of Continuous Manufacturing Related Service, 2020-2030
17.4.4. Distribution
by Key Geographical Regions, 2020-2030
17.5. Continuous
Manufacturing Market for Biologic, 2020-2030
17.5.1. Distribution
by Purpose of Manufacturing, 2020-2030
17.5.2. Distribution
by Scale of Operation, 2020-2030
17.5.3. Distribution
by Type of Continuous Manufacturing Related Service, 2020-2030
17.5.4. Distribution
by Key Geographical Regions, 2020-2030
18. CONCLUSION
18.1. Chapter
Overview
18.2. Key
Takeaways
19. EXECUTIVE
INSIGHTS
19.1. Chapter
Overview
19.2. Zaiput Flow
Technologies
19.2.1. Company
Snapshot
19.2.2. Interview
Transcript: Andrea Adamo, Founder and Chief Executive Officer
19.3. CONTINUUS
Pharmaceuticals
19.3.1. Company
Snapshot
19.3.2. Interview
Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer
19.4. Snapdragon
Chemistry
19.4.1. Company
Snapshot
19.4.2. Interview
Transcript: Eric Fang, Chief Scientific Officer
19.5. Enzene
Biosciences
19.5.1. Company
Snapshot
19.5.2. Interview
Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
19.6. Pfizer
19.6.1. Company Snapshot
19.6.2. Interview
Transcript: Nick Thomson, Senior Director Chemical Research and Development
19.7. University
of Strathclyde
19.7.1. Company
Snapshot
19.7.2. Interview
Transcript: Ian Houson, Technical Project Manager
20. APPENDIX 1:
TABULATED DATA
21. APPENDIX 2:
LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415